|
1
|
Mao X, Hou T, Liu N, Liu Y, Zhang J, Deng W, Dong W, Peng H. Psychological health of healthcare workers during Shanghai lockdown: Prevalence and associated factors. PSYCHOL HEALTH MED 2025; 30:834-847. [PMID: 39980465 DOI: 10.1080/13548506.2025.2458250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Accepted: 01/20/2025] [Indexed: 02/22/2025]
Abstract
The 2022 Shanghai COVID-19 lockdown may lead to mental health issues among healthcare workers (HCWs). A cross-sectional study was conducted to investigate psychological health and its associated factors among HCWs. A total of 253 hCWs were recruited in Shanghai, China, through convenience sampling method. Demographic Questionnaire, Generalized Anxiety Disorder-7, Patient Health Questionnaire-9, Insomnia Severity Index, and The Impact of Event Scale-Revised were used to assess demographic information, anxiety, depression, insomnia, and post-traumatic stress disorder (PTSD), respectively. The associated factors of psychological health were identified by binary logistic regression analysis. The prevalence of anxiety, depression, insomnia, and PTSD was 6.3%, 10.3%, 9.9% and 17.8%, respectively. Female HCWs were more likely to report anxiety (OR = 5.50, 95%CI = [1.45-20.82], p < 0.05) and PTSD (OR = 3.20, 95%CI= [1.23-8.28], p < 0.05). Besides, being a nurse was associated with a lower level of PTSD symptoms (OR = 0.23, 95%CI = [0.07-0.76], p < 0.05). Symptoms of psychological health were screened positive in HCWs during the 2022 Shanghai COVID-19 lockdown. Gender and occupation were associated with psychological health. The hospital authorities of Shanghai need to pay special attention to female HCWs.
Collapse
Affiliation(s)
- Xiaofei Mao
- Faculty of Psychology, Naval Medical University, Shanghai, China
| | - Tianya Hou
- Faculty of Psychology, Naval Medical University, Shanghai, China
| | - Ning Liu
- Department of Orthopedics, The 960th hospital of Joint Logistics Support Force, Jinan, China
| | - Yueyang Liu
- School of Basic Medical Science, Naval Medical University, Shanghai, China
| | - Jianguo Zhang
- Faculty of Psychology, Naval Medical University, Shanghai, China
| | - Wenxi Deng
- Faculty of Psychology, Naval Medical University, Shanghai, China
| | - Wei Dong
- Faculty of Psychology, Naval Medical University, Shanghai, China
| | - Huamao Peng
- Institute of Developmental Psychology, Beijing Normal University, Beijing, China
| |
Collapse
|
|
2
|
Hatabah D, Gupta SL, Mantus G, Sullivan P, Heilman S, Camacho-Gonzalez A, Leake D, Le M, Griffiths M, Norwood C, Shih S, Korman R, Maziashvili G, Rees CA, Benedit L, Wynn BA, Suthar M, Vos MB, Wrammert J, Morris CR. Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers. Vaccines (Basel) 2025; 13:163. [PMID: 40006710 PMCID: PMC11861628 DOI: 10.3390/vaccines13020163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2024] [Revised: 01/27/2025] [Accepted: 02/05/2025] [Indexed: 02/27/2025] Open
Abstract
Background: Vaccines against COVID-19 target the spike protein. There is minimal information on longitudinal COVID-19 immune profiling in recovered versus naïve and vaccinated versus non-vaccinated healthcare workers (HCWs). Methods: This is a prospective longitudinal observational cohort of pediatric HCWs (pHCWs) conducted during 2020-2022 at an academic center, exploring the impact of COVID-19 vaccination on immunoglobulin G (IgG) antibody titers over time and cross-reactivity with other coronaviruses, including SARS-CoV-1, MERS-CoV, and seasonal coronaviruses (HCoV-HKU1 and HCoV-OC43). Results: A total of 642 pHCWs initially enrolled, and 337 participants had repeat IgG titers measured post-vaccine and post-booster. Most participants were female, median age range of 31-40 years. Anti-spike was higher in all vaccinated individuals versus non-vaccinated (p < 0.0001) and naïve versus infected (p < 0.0001). A single dose of vaccine was sufficient to attain maximum titers in recovered participants versus naïve who received both doses of vaccine. Anti-spike titers dropped significantly at 9 months after the primary series, whereas sustained anti-spike titers were observed at 9 months post-booster. Conclusions: All vaccinated pHCWs developed antibodies to spike. COVID-19 infection and/or vaccination yielded antibodies that cross-reacted to SARS-CoV-1, MERS-CoV, HCoV-HKU1, and HCoV-OC43. Anti-spike titers were more durable post-booster compared to the primary series. Longitudinal immune profiling of COVID-19 responses provides vital data to shape public health policies, optimize vaccine strategies, and strengthen pandemic preparedness.
Collapse
Affiliation(s)
- Dunia Hatabah
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
| | - Sneh Lata Gupta
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
| | - Grace Mantus
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
| | - Patrick Sullivan
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30329, USA;
| | - Stacy Heilman
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
| | - Andres Camacho-Gonzalez
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
- Children’s Healthcare of Atlanta, Atlanta, GA 30329, USA; (D.L.); (L.B.)
| | - Deborah Leake
- Children’s Healthcare of Atlanta, Atlanta, GA 30329, USA; (D.L.); (L.B.)
| | - Mimi Le
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
| | - Mark Griffiths
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Children’s Healthcare of Atlanta, Atlanta, GA 30329, USA; (D.L.); (L.B.)
| | - Carson Norwood
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
| | - Samuel Shih
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
| | - Rawan Korman
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
| | - Giorgi Maziashvili
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
| | - Chris A. Rees
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Children’s Healthcare of Atlanta, Atlanta, GA 30329, USA; (D.L.); (L.B.)
| | - Laura Benedit
- Children’s Healthcare of Atlanta, Atlanta, GA 30329, USA; (D.L.); (L.B.)
| | - Bridget A. Wynn
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
| | - Mehul Suthar
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
| | - Miriam B. Vos
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Children’s Healthcare of Atlanta, Atlanta, GA 30329, USA; (D.L.); (L.B.)
- Center for Clinical and Translational Research of Children’s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
| | - Jens Wrammert
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
| | - Claudia R. Morris
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; (D.H.); (S.L.G.); (G.M.); (S.H.); (A.C.-G.); (M.L.); (M.G.); (C.N.); (S.S.); (R.K.); (G.M.); (C.A.R.); (B.A.W.); (M.S.); (M.B.V.); (J.W.)
- Children’s Healthcare of Atlanta, Atlanta, GA 30329, USA; (D.L.); (L.B.)
- Center for Clinical and Translational Research of Children’s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
| |
Collapse
|
|
3
|
Parsons Leigh J, FitzGerald EA, Moss SJ, Cherak MS, Brundin-Mather R, Dodds A, Stelfox HT, Dubé È, Fiest KM, Halperin DM, Ahmed SB, MacDonald SE, Straus SE, Manca T, Ng Kamstra J, Soo A, Longmore S, Kupsch S, Sept B, Halperin SA. The evolution of vaccine hesitancy through the COVID-19 pandemic: A semi-structured interview study on booster and bivalent doses. Hum Vaccin Immunother 2024; 20:2316417. [PMID: 38390696 PMCID: PMC10896168 DOI: 10.1080/21645515.2024.2316417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 02/06/2024] [Indexed: 02/24/2024] Open
Abstract
We sought in-depth understanding on the evolution of factors influencing COVID-19 booster dose and bivalent vaccine hesitancy in a longitudinal semi-structured interview-based qualitative study. Serial interviews were conducted between July 25th and September 1st, 2022 (Phase I: univalent booster dose availability), and between November 21st, 2022 and January 11th, 2023 (Phase II: bivalent vaccine availability). Adults (≥18 years) in Canada who had received an initial primary series and had not received a COVID-19 booster dose were eligible for Phase I, and subsequently invited to participate in Phase II. Twenty-two of twenty-three (96%) participants completed interviews for both phases (45 interviews). Nearly half of participants identified as a woman (n = 11), the median age was 37 years (interquartile range: 32-48), and most participants were employed full-time (n = 12); no participant reported needing to vaccinate (with a primary series) for their workplace. No participant reported having received a COVID-19 booster dose at the time of their interview in Phase II. Three themes relating to the development of hesitancy toward continued vaccination against COVID-19 were identified: 1) effectiveness (frequency concerns; infection despite vaccination); 2) necessity (less threatening, low urgency, alternate protective measures); and 3) information (need for data, contradiction and confusion, lack of trust, decreased motivation). The data from interviews with individuals who had not received a COVID-19 booster dose or bivalent vaccine despite having received a primary series of COVID-19 vaccines highlights actionable targets to address vaccine hesitancy and improve public health literacy.
Collapse
Affiliation(s)
- Jeanna Parsons Leigh
- Faculty of Health, School of Health Administration, Dalhousie University, Halifax, Nova Scotia, Canada
- Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada
- Canadian Center for Vaccinology & IWK Health Center, Halifax, Nova Scotia, Canada
| | - Emily A. FitzGerald
- Faculty of Health, School of Health Administration, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Stephana Julia Moss
- Faculty of Health, School of Health Administration, Dalhousie University, Halifax, Nova Scotia, Canada
- CRISMA Center, Department of Critical Care, University of Pittsburgh, Pittsburgh, USA
| | - Michal S. Cherak
- Faculty of Health, School of Health Administration, Dalhousie University, Halifax, Nova Scotia, Canada
- Canadian Center for Vaccinology & IWK Health Center, Halifax, Nova Scotia, Canada
| | | | - Alexandra Dodds
- Faculty of Health, School of Health Administration, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Henry T. Stelfox
- Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada
- Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Ève Dubé
- Centre de Recherche du CHU de Québec, Université Laval, Québec, Canada
- Département d’anthropologie, Université Laval, Québec, Canada
| | - Kirsten M. Fiest
- Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada
- O’Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada
- Department of Psychiatry & Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Donna M. Halperin
- Canadian Center for Vaccinology & IWK Health Center, Halifax, Nova Scotia, Canada
- Rankin School of Nursing, St. Francis Xavier University, Antigonish, Nova Scotia, Canada
| | - Sofia B. Ahmed
- Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
- Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Shannon E. MacDonald
- School of Public Health, University of Alberta, Edmonton, Alberta, Canada
- Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
| | - Sharon E. Straus
- Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario, Canada
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada
- Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Terra Manca
- Faculty of Health Disciplines, Athabasca University, Athabasca, Alberta, Canada
- Sociology and Social Anthropology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Josh Ng Kamstra
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Andrea Soo
- Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada
- Alberta Health Services, Calgary, Alberta, Canada
| | - Shelly Longmore
- Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Shelly Kupsch
- Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Bonnie Sept
- Department of Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Scott A. Halperin
- Canadian Center for Vaccinology & IWK Health Center, Halifax, Nova Scotia, Canada
- Department of Pediatrics, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
- Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
| |
Collapse
|
|
4
|
Christodoulakis A, Bouloukaki I, Aravantinou-Karlatou A, Zografakis-Sfakianakis M, Tsiligianni I. Vaccine Hesitancy and Associated Factors Amongst Health Professionals: A Scoping Review of the Published Literature. Vaccines (Basel) 2024; 12:1411. [PMID: 39772072 PMCID: PMC11680286 DOI: 10.3390/vaccines12121411] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2024] [Revised: 12/05/2024] [Accepted: 12/11/2024] [Indexed: 01/11/2025] Open
Abstract
Background/Objectives: Healthcare professionals (HCPs) hold significant influence over public attitudes toward vaccinations. Studies suggest that HCPs are hesitant towards the coronavirus disease 2019 (COVID-19) vaccines. This hesitancy could lead to lower vaccination rates in the community. Therefore, this scoping review aimed to assess the extent of hesitancy towards COVID-19 booster doses among HCPs and identify the associated factors. Methods: A comprehensive search was conducted in the PubMed and Scopus databases from April to August 2024, using keywords related to COVID-19, vaccine hesitancy, HCPs, and booster vaccination. Studies that had been peer-reviewed, published in English after 2022, and focused on the hesitancy of the COVID-19 booster dose hesitancy among HCPs were included. Out of the 6703 studies screened, 24 studies were included. Results: Most of the HCPs have received their initial series of COVID-19 vaccinations. However, there is a lower rate of uptake for booster doses, with hesitancy rates ranging from 12% to 66.5%. Hesitancy rates varied significantly across continents, with Asia, Africa, and Europe ranging from 19.7% to 66.5%, 27% to 46.1%, 14% to 60.2%, respectively. Hesitancy was reported to be influenced by various factors, including concerns about vaccine safety, necessity, and effectiveness of these vaccines. In addition, the hesitancy regarding booster doses was also found to be influenced by factors like age, gender, profession, and previous COVID-19. Physicians, nurses, and pharmacists exhibited vaccine hesitancy rates ranging from 12.8% to 43.7%, 26% to 37%, and 26% to 34.6%, respectively. Conclusions: Our review underscores the hesitancy among HCPs towards receiving booster doses across countries around the world and explores the underlying factors. These findings provide valuable insights for the design of future pandemic vaccination programs.
Collapse
Affiliation(s)
- Antonios Christodoulakis
- Department of Social Medicine, School of Medicine, University of Crete, 71500 Heraklion, Greece; (A.C.); (A.A.-K.); (I.T.)
- Department of Nursing, School of Health Sciences, Hellenic Mediterranean University, 71410 Heraklion, Greece;
| | - Izolde Bouloukaki
- Department of Social Medicine, School of Medicine, University of Crete, 71500 Heraklion, Greece; (A.C.); (A.A.-K.); (I.T.)
| | - Antonia Aravantinou-Karlatou
- Department of Social Medicine, School of Medicine, University of Crete, 71500 Heraklion, Greece; (A.C.); (A.A.-K.); (I.T.)
| | | | - Ioanna Tsiligianni
- Department of Social Medicine, School of Medicine, University of Crete, 71500 Heraklion, Greece; (A.C.); (A.A.-K.); (I.T.)
| |
Collapse
|
|
5
|
Zheng H, Wu S, Chen W, Cai S, Zhan M, Chen C, Lin J, Xie Z, Ou J, Ye W. Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection. Front Public Health 2024; 12:1457266. [PMID: 39253287 PMCID: PMC11381385 DOI: 10.3389/fpubh.2024.1457266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2024] [Accepted: 08/13/2024] [Indexed: 09/11/2024] Open
Abstract
Background Hybrid immunity (a combination of natural and vaccine-induced immunity) provides additional immune protection against the coronavirus disease 2019 (COVID-19) reinfection. Today, people are commonly infected and vaccinated; hence, hybrid immunity is the norm. However, the mitigation of the risk of Omicron variant reinfection by hybrid immunity and the durability of its protection remain uncertain. This meta-analysis aims to explore hybrid immunity to mitigate the risk of Omicron variant reinfection and its protective durability to provide a new evidence-based basis for the development and optimization of immunization strategies and improve the public's awareness and participation in COVID-19 vaccination, especially in vulnerable and at-risk populations. Methods Embase, PubMed, Web of Science, Chinese National Knowledge Infrastructure, and Wanfang databases were searched for publicly available literature up to 10 June 2024. Two researchers independently completed the data extraction and risk of bias assessment and cross-checked each other. The Newcastle-Ottawa Scale assessed the risk of bias in included cohort and case-control studies, while criteria recommended by the Agency for Health Care Research and Quality (AHRQ) evaluated cross-sectional studies. The extracted data were synthesized in an Excel spreadsheet according to the predefined items to be collected. The outcome was Omicron variant reinfection, reported as an Odds Ratio (OR) with its 95% confidence interval (CI) and Protective Effectiveness (PE) with 95% CI. The data were pooled using a random- or fixed-effects model based on the I2 test. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Results Thirty-three articles were included. Compared with the natural immunity group, the hybrid immunity (booster vaccination) group had the highest level of mitigation in the risk of reinfection (OR = 0.43, 95% CI:0.34-0.56), followed by the complete vaccination group (OR = 0.58, 95% CI:0.45-0.74), and lastly the incomplete vaccination group (OR = 0.64, 95% CI:0.44-0.93). Compared with the complete vaccination-only group, the hybrid immunity (complete vaccination) group mitigated the risk of reinfection by 65% (OR = 0.35, 95% CI:0.27-0.46), and the hybrid immunity (booster vaccination) group mitigated the risk of reinfection by an additional 29% (OR = 0.71, 95% CI:0.61-0.84) compared with the hybrid immunity (complete vaccination) group. The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88-46.89%) within 270-364 days, and decreased to 33.23%% (95% CI, 23.80-42.66%) within 365-639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82-57.90%) within 270-364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95-78.04%) within 90-119 days. Conclusion Hybrid immunity was significantly more protective than natural or vaccination-induced immunity, and booster doses were associated with enhanced protection against Omicron. Although its protective effects waned over time, vaccination remains a crucial measure for controlling COVID-19. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/, identifier, CRD42024539682.
Collapse
Affiliation(s)
- Huiling Zheng
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
- School of Public Health, Fujian Medical University, Fuzhou, China
| | - Shenggen Wu
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
| | - Wu Chen
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
| | - Shaojian Cai
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
| | - Meirong Zhan
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
| | - Cailin Chen
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
| | - Jiawei Lin
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
| | - Zhonghang Xie
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
| | - Jianming Ou
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
| | - Wenjing Ye
- Institute of Emergency Response and Epidemic Management, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China
| |
Collapse
|
|
6
|
Deng JS, Huang CL, Hu QY, Shi L, Chen XY, Luo X, Tung TH, Zhu JS. Impact of prior SARS-CoV-2 infection on college students' hesitancy to receive additional COVID-19 vaccine booster doses: A study from Taizhou, China. Prev Med Rep 2024; 41:102709. [PMID: 38576514 PMCID: PMC10992892 DOI: 10.1016/j.pmedr.2024.102709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 03/27/2024] [Accepted: 03/28/2024] [Indexed: 04/06/2024] Open
Abstract
PURPOSE This study aimed to examine the impact of a history of SARS-CoV-2 infection on the hesitancy of college students to receive additional COVID-19 vaccine booster doses. METHODS A population-based self-administered online survey was conducted in July 2024 in Taizhou, China. A total of 792 respondents were included in this study. Logistic regression was conducted to identify factors associated with college students' hesitation to receive booster doses of the COVID-19 vaccine. RESULTS Of 792 respondents, 32.2 % hesitated to receive additional doses of the COVID-19 vaccine booster. Furthermore, 23.5 % of the respondents reported an increase in hesitancy to receiving additional COVID-19 vaccine booster doses compared to before they were infected with SARS-CoV-2. In the regression analyses, college students who had a secondary infection were more hesitant to receive additional COVID-19 vaccine booster doses (OR = 0.481, 95 % CI: (0.299-0.774), P = 0.003). Moreover, students with secondary infections who were male (OR = 0.417, 95 % CI: 0.221-0.784, P = 0.007), with lower than a bachelor's degree (OR = 0.471, 95 % CI: 0.272-0.815, P = 0.007), in non-medical majors (OR = 0.460, 95 % CI: 0.248-0.856, P = 0.014), and sophomores or below (OR = 0.483, 95 % CI: 0.286-0.817, P = 0.007) were more hesitant to receive additional COVID-19 vaccine booster doses. CONCLUSION A history of SARS-CoV-2 infection affects college students' hesitation to receive additional COVID-19 vaccine booster doses, which was higher in those who experienced secondary infections.
Collapse
Affiliation(s)
- Jing-Shan Deng
- Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang 317000, China
| | - Chun-Lian Huang
- Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang 317000, China
| | - Qiong-Ying Hu
- School of Medicine, Taizhou University, 1139 Shifu Road, Jiaojiang District, Taizhou, Zhejiang 318000, China
| | - Lei Shi
- Enze Nursing College, Taizhou Vocational and Technical College, Taizhou, Zhejiang 318000, China
| | - Xiao-Ying Chen
- Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang 317000, China
| | - Xu Luo
- Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang 317000, China
| | - Tao-Hsin Tung
- Evidence-based Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang 317000, China
| | - Jian-Sheng Zhu
- Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang 317000, China
| |
Collapse
|
|
7
|
Li S, Hao J, Su Y, Zhan H, Zhou N, Qiu Y, Lu Y, Sun K, Tian Y. COVID-19 vaccine hesitancy and influencing factors among Chinese hospital staff: a cross-sectional study. Sci Rep 2024; 14:4369. [PMID: 38388666 PMCID: PMC10883913 DOI: 10.1038/s41598-024-55001-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Accepted: 02/19/2024] [Indexed: 02/24/2024] Open
Abstract
We aimed to investigate the willingness of hospital staff to receive the COVID-19 vaccine and explore the associated factors and reasons of vaccine hesitancy among Chinese hospital staff, which were not yet known. A cross-sectional questionnaire survey was conducted online on the vaccine hesitancy of staff in a grade A tertiary general hospital in Beijing from February 22 to 23, 2023. Univariate and multivariate logistic regression were used to assess associations between potential influencing factors and vaccine hesitancy. A total of 3269 valid respondents were included, and the rate of COVID-19 vaccine hesitancy was 32.67%. Multivariate logistic regression showed that women [1.50 (1.22-1.83)], having high-school education level [1.69 (1.04-2.76)], college degree [2.24 (1.35-3.72)] or graduate degree [2.31 (1.33-4.03)], and having underlying disease [1.41 (1.12-1.77)] were associated with a higher rate of COVID-19 vaccine hesitancy. The main reasons for vaccine hesitancy included doubts for the safety and effectiveness of COVID-19 vaccine and worries in adverse reactions. Hospital staff's willingness to vaccinate COVID-19 vaccine is generally high in the study. Hospitals should spread the knowledge of COVID-19 vaccine through multiple channels to improve the cognition of hospital staff and encourage vaccination based on associated factors.
Collapse
Affiliation(s)
- Shangyao Li
- School of Public Health, Capital Medical University, 10 You'anmen Outer West 1st Street, Beijing, 100069, China
| | - Jinjuan Hao
- Hospital Administration Office, Beijing Hospital, National Center of Gerontology, Institute of Geriatrics Medicine, Chinese Academy of Medical Sciences, 1 Dahua Road, Dongdan, Beijing, 100730, China
| | - Yu Su
- School of Public Health, Capital Medical University, 10 You'anmen Outer West 1st Street, Beijing, 100069, China
| | - Haoran Zhan
- School of Public Health, Capital Medical University, 10 You'anmen Outer West 1st Street, Beijing, 100069, China
| | - Nuo Zhou
- School of Public Health, Capital Medical University, 10 You'anmen Outer West 1st Street, Beijing, 100069, China
| | - Yitong Qiu
- School of Public Health, Capital Medical University, 10 You'anmen Outer West 1st Street, Beijing, 100069, China
| | - Yitong Lu
- School of Public Health, Capital Medical University, 10 You'anmen Outer West 1st Street, Beijing, 100069, China
| | - Ke Sun
- Hospital Administration Office, Beijing Hospital, National Center of Gerontology, Institute of Geriatrics Medicine, Chinese Academy of Medical Sciences, 1 Dahua Road, Dongdan, Beijing, 100730, China.
| | - Yu Tian
- School of Public Health, Capital Medical University, 10 You'anmen Outer West 1st Street, Beijing, 100069, China.
| |
Collapse
|